Investigational drug · Phase 2
VIS954
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Inflammatory Skin Diseases.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "VIS954"
First trial start
2026
Nov 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VIS954", any sponsor or status.
Conditions studied
As listed on its trial records.
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Inflammatory Skin Diseases
Approved drugs for the same conditions: Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "VIS954" as an intervention, largest first.
- VIS954 for Treating Inflammatory Skin ProblemsPivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07933445 · 108 participants (planned) · Start Nov 30, 2026 · Primary completion Mar 13, 2029
Drug: VIS954; Placebo · For: Inflammatory Skin Diseases
- Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated VasculitisNot yet recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07904806 · 75 participants (planned) · Start Dec 15, 2026 · Primary completion Nov 20, 2029
Drug: VIS954; Standard Of Care (SOC) and 1 more · For: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06212804 · 54 participants · Start Nov 21, 2023 · Primary completion Jul 19, 2024
Drug: VIS954 · For: Healthy Volunteers
Sites: Anaheim, California
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06937593 · 24 participants · Start Mar 13, 2025 · Primary completion Feb 3, 2026
Drug: VIS954; Placebo · For: Healthy
Sites: Anaheim, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- NKX019Phase 22 trials
Nkarta, Inc. · Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Otsuka.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.